irishtimes.com - Last Updated: Friday, July 27, 2012, 10:08
Irish drug company Amarin has won US approval for its first drug, a treatment to help combat high levels of blood fat that can lead to stroke and heart attack.
The Food and Drug Administration last night cleared Vascepa as an adjunct to diet for a condition known as very high triglycerides, the company said in a statement.
The medication will compete with GlaxoSmithKline's Lovaza. Amarin anticipates starting sales in the first quarter of 2013, chief executive Joseph Zakrzewski said in the statement.
Vascepa may have an advantage because it doesn't raise bad cholesterol levels, a possible side effect for Lovaza, Jon Lecroy, an analyst with MKM Partners in Stamford, Connecticut, said in an interview.
Amarin's drug has the potential to reach sales of $1.25 billion in 2017, which may lead to acquisition offers for the Dublin-based company from drugmakers including AstraZeneca, Mr Lecroy said ahead of the approval.
"There will be interest from large pharmaceutical companies," Mr Lecroy said. "Any company with a large cardiovascular or diabetes sales force makes sense. That's almost any."
AstraZeneca, based in London, may be an option because of its best-selling cholesterol medication Crestor, Lecroy said. Crestor is a statin, and Amarin's drug may be used in a combination with statins. Crestor had $6.6 million in sales last year, according to data compiled by Bloomberg.
Pfizer may also be a candidate to buy Amarin to replace revenue lost from expiring patent protection for its $9.6 billion drug Lipitor, as is Abbott Laboratories, which has an existing cardiovascular franchise, said Akiva Felt, an analyst with Wedbush Securities in Los Angeles, in an interview.
Amarin is still considering an acquisition, a partnership or bringing Vascepa to market itself, Mr Zakrzewski said.
See the original post:
Amarin stroke drug wins approval